I am continually bemused how prana is always overlooked in these type of articles. Imagine the type of article that would have been written if LLY's new candidate was substituted with PBT2!!
Here we are sitting on a drug that has pretty much driven the whole amyloid theory, is heading into late stage testing with some pretty impressive results so far, yet we struggle to attract investors.
What is it? A lack of marketing ability from prana? Holding out for a better price as PoS suggests?
It's very frustrating but right now I am comforted knowing we are probably the lead candidate with strong evidence to date.
I am continually bemused how prana is always overlooked in these...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $38.48K | 12.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 77190096 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 6269051 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |